Products - Skin infections | Topic | NICE

Showing 5 products

Date | Title

Guidance programme: Technology appraisal guidanceRemove ‘Guidance programme: Technology appraisal guidance’ filter
Status: PublishedRemove ‘Status: Published’ filter

Bimekizumab for treating moderate to severe hidradenitis suppurativa (terminated appraisal) (TA1028)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
15 January 2025
Dupilumab for treating moderate to severe prurigo nodularis (TA955)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
13 March 2024
Secukinumab for treating moderate to severe hidradenitis suppurativa (TA935)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
6 December 2023
Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma (TA720)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
18 August 2021
Adalimumab for treating moderate to severe hidradenitis suppurativa (TA392)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 June 2016